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BACKGROUND: Constitutive activation of RhoA-dependent RhoA kinase (ROCK) signalling is known to promote cellular
transformation and the ROCK inhibitor Y-27632 has the ability to suppress focus formation of RhoA transformed NIH3T3 cells.
METHODS: Sixty-four novel structural analogues of Y27632 were synthesised and tested for their ability to persistently inhibit the
transformation of NIH3T3 cells by Rho guanidine exchange factor 16 (ARHGEF16) or Ras. In vitro kinase inhibitor profiling, co-culture
of transformed cells with non-transformed cells and a novel Lucifer yellow/PKH67 dye transfer method were used to investigate their
mode of action.
RESULTS: Four Y27632 analogues inhibited transformed focus formation that persisted when the compound was withdrawn. No
toxicity was observed against either transformed or non-transformed cells and the effect was dependent on co-culture of these two
cell types. In vitro kinase inhibitor profiling indicated that these compounds had reduced activity against ROCK compared with
Y27632, targeting instead Aurora A (AURKA), p38 (MAPK14) and Hgk (MAP4K4). Dye transfer analysis showed they increased gap
junction intercellular communication (GJIC) between transformed and non-transformed cells.
CONCLUSIONS: These data are the first to suggest that transient blockade of specific kinases can induce a persistent inhibition of non-
contact inhibited transformed colony formation and can also remove pre-formed colonies. These effects could potentially be
mediated by the observed increase in GJIC between transformed and non-transformed cells. Selection of kinase inhibitors with this
property may thus provide a novel strategy for cancer chemoprevention.
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The non-transformed murine fibroblast NIH3T3 cell line has been
used for many years as a standard assay for the ability of either
chemicals and/or targeted alterations of gene expression to induce
cellular transformation (Rubin and Xu, 1989). Compared with
many other cell systems, malignant conversion of these cells
occurs with relative ease. It is usually measured by loss of cell–cell
contact growth inhibition, producing colonies or multilayered
domes that grow to increased saturation density (Rubin and Xu,
1989). Cells with these properties will typically form tumours when
transplanted into nude mice (Rubin, 2005). NIH3T3 cells have
been transformed by ectopic expression of many different kinds of
gene product and it is particularly relevant to this study that forced
expression of proteins, which disturb normal gap junction
intercellular communication (GJIC), such as ductin, can transform
these cells (Saito et al, 1998). Indeed, disruption of GJIC is a
common feature of malignant conversion per se with the corollary
that suppression of transformed cell characteristics can occur
when GJIC is established between transformed and non-trans-
formed cells (Yamasaki, 1991; Sakamoto et al, 1999).
Earlier studies have also shown that constitutive expression of
activated RhoA mutants or guanidine exchange factors can
transform NIH3T3 cells and that the formation of transformed
colonies can be inhibited by the RhoA kinase (ROCK) inhibitor
Y27632 (Sahai et al, 1999). Y27632 is a structural analogue of ATP,
which has been shown to have potent inhibitory activity against
both ROCK’s 1 and 2 (Uehata et al, 1997; Ishizaki et al, 2000).
The role of ROCK activation in the process of tumour invasion is
well established (Sahai and Marshall, 2002; Croft et al, 2004)
and there have been several studies on the anti-metastatic
potential of Y27632 (Itoh et al, 1999; Lawler et al, 2006;
Ogawa et al, 2007). Collectively these data indicate that
inappropriate activation of RhoA and thus ROCK proteins may
have a role not only in the invasive potential of tumour
cells, but also in malignant transformation. A summary of the
prospective role of Rho proteins in carcinogenesis is described in
Benitah et al (2004).
We had shown earlier that interaction of the HPV16 E6
oncoprotein with the PDZ domain protein, Tip-1, may be linked
to increased cell motility caused by the activation of RhoA.
Furthermore, this increased motility could be inhibited by the
ROCK inhibitor Y27632 (Hampson et al, 2004). Additional work
identified the guanidine exchange factor ARHGEF16 (GEF16) as a
novel binding partner for Tip-1 (manuscript in preparation). Thus, Revised 29 May 2009; accepted 30 June 2009
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swhen it was observed that transfection of NIH3T3 cells with GEF16
could induce the formation of transformed colonies, we decided to
investigate the sensitivity of these transformants to Y27632 and
a range of de novo synthesised, ATP based, structural Y27632
analogues.
MATERIALS AND METHODS
Cell culture and stable gene transfection
The NIH3T3 mouse fibroblast cell line was cultured in DMEM
containing 10% bovine serum supplemented with 2mM
L-glutamine and grown at 371C in humidified air containing 5%
CO2. The full-length GEF16 open reading frame (Accession
NM_014448) was PCR amplified, sequence verified and sub-cloned
into the mammalian expression vector pCMVTag (Invitrogen Ltd.,
Paisley, UK). The pCMVTag-GEF16 cDNA construct or the LZR-
MS-IRES-ZEO/pBR-Ras construct (A kind gift of Dr A Malliri;
PICR, Manchester, UK) was then used to transfect NIH3T3 cells
using Lipofectamine according to the manufacturer’s recommen-
dations (Invitrogen Ltd.). GEF16, Ras and vector control
transfected cells were then maintained in the presence of G418
or Zeocin for 10 days. Polyclonal GEF16, Ras and vector
transfectants were expanded in sub-confluent cultures and
 801C freezer stocks taken. Individual GEF16 transformed
colonies were isolated by the use of cloning rings, expanded in
culture and  801C frozen stocks also taken for storage.
RT–PCR
Total cellular RNAs were prepared using the SuperScript III cells
direct cDNA synthesis kit as recommended by the manufacturer
(Ambion, Cambridgeshire, UK). Total RNAs from cells were isolated
using Trizol reagent (Invitrogen Ltd.). All DNAase I-treated RNAs
were then reverse transcribed with random decamers. Polymerase
chain reaction was performed in 20ml of a reaction mixture
containing 2ml of reverse-transcribed product, 10mlo f2  Bio-Red
(bioline Ltd., London, UK) and 0.1mM of each primer. The specific
primers for GEF16 and b-actin were as follows:
GEF16 forward: 5-ACCACCACCTCTTCTCCAAC-30
GEF16 reverse: 50-TCGTTGGAGCAGTAGGCGAT-30
b-actin forward: 50-TCC ATC ATG AAG TGT GAC GT-30
b-actin reverse: 50-TCA GGA GGA GCA ATG ATC TT-30
The reaction mixture was denatured at 941C for 4min then
amplified for 32 cycles of 30s denaturation at 941C, 30s annealing
at 551C and 30s extension at 721C, followed by a single 5min
extension at 721C.
Transformed colony forming assay
Polyclonal vector or GEF16 transfected NIH3T3 cells were seeded
separately in 30mm dishes at a density of 2 10
5 cells per well and
grown to full confluence in the presence of either 10mM Y27632
(Calbiochem, Darmstadt, Germany), Y27632 analogues (YA1, YA2,
YA3, YA4) or DMSO control. Medium plus inhibitors or DMSO
control was changed every 2 days and foci formation analysed by
Toluidine blue (Sigma-Aldrich, Poole, UK) staining after 10 days
growth post-confluence. Each assay was performed in triplicate
and the data shown is representative of at least three separate
experiments.
In vitro ROCK activity assay
Rho-kinase activity was determined using an immunoassay as
recommended by the manufacturer (CycLex Co., Ltd., Nagano,
Japan). Briefly, 100ml samples containing 10mUnit of recombinant
ROCK with or without inhibitors were aliquoted into a 96-well
plate, pre-coated with threonine Rho-kinase phosphorylation
substrate. After 30min incubation at 301C, the plate was washed
three times with PBS then incubated with 100ml/well of HRP-
conjugated anti-phospho-specific antibody for 1h at room
temperature. The amount of phosphorylated substrate was
determined by adding 100ml/well of substrate reagent for 10min
and the reaction was terminated by adding 100ml/well of the stop
solution. The absorbance was measured on a 96-well plate reader
at 450nm (Dynex Technologies, West Sussex, UK). Each data point
was performed in triplicate and the assay was repeated twice.
SelectScreen in vitro kinase profiling
The SelectScreen kinase inhibitor assay service was used (Invitro-
gen Ltd.). The YA compounds were diluted in DMSO at a
concentration of 10mM and single-point kinase inhibitory
activities were measured at 10mM and Km ATP concentration.
Cell proliferation assay
Cell proliferation was measured Celltiter Aq
96 reagent (Promega,
Southhampton, UK) according to the manufacturer’s protocol.
Cells were seeded into a 96-well plate at a density of 1 10
3 cells/
well allowing three wells per data point and allowed to attach for a
set period. After this, the initial starting point 490nm absorbance
was determined by adding 20mlo fA q
96 reagent to each well and
incubating for 4h at 371Ci n5 %C O 2 (96-well plate reader, Dynex
Technologies). The various compounds or DMSO control were
then added to the wells and the absorbance determined in the same
way at the time points indicated. Each data set shown is
representative of three separate experiments.
Flow cytometry
NIH3T3 cells with or without drug treatments were collected at
various time points and cell counts carried out to confirm that
1 10
6 cells were present for each cytometric analysis. Cells were
washed with PBS, fixed with 70% ice-cold ethanol, pelleted and
stained with propidium iodide (10mgml
 1) (Sigma-Aldrich) at
41C for 45min. Cells were then washed twice with ice-cold PBS and
resuspended in 400ml of PBS. The DNA content during different
phases of the cell cycle was then determined by flow cytometry
FACSConto (BD Biosciences, Oxford, UK). Each profile shown was
a representative of three separate experiments.
Quantitative analysis of GJIC
A flow cytometric assay was developed to measure the extent of
GJIC using two differentially stained cell populations. Non-
transformed recipient NIH3T3-vector cells were stained with
PKH67 (excitation 490, emission 502, Sigma-Aldrich) and GEF16
transformed donor cells were stained with Lucifer yellow (LY)
(excitation 427nm, emission 517nm, Invitrogen Ltd.). A 1ml
suspension of 1 10
7 recipient cells in serum-free DMEM was
mixed with an equal volume of 4mM PKH67 solution and incubated
for 5min at room temperature. The reaction was terminated by
adding 2ml serum and incubating for 1min. Cells were then
washed three times with culture medium, and seeded at 1.5 10
6
cells/T-25 flask. For LY staining of transformed donor cells, 700ml
of 5 10
6 cells were mixed with 100ml of 8mgml
 1 LY solution in
a 4mm gap electroporation cuvette (EquiBIO, Middlesex, UK) and
this was kept on ice for 5min followed by electroporation at 400V
(1000Vcm
 1) (Gene Transformer, Savant Instruments Inc., NY,
USA). Fresh medium was added and the cells were seeded in a T-25
flask and were allowed to recover overnight at 371C. Lucifer
yellow-labelled donor cells were then collected and 1 10
5 were
added to the T-25 flask containing the PKH67-labelled recipient
cells plus 10mM YA1 or DMSO control. After incubating for various
time intervals, the co-cultured donor and recipient cells were
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scollected and analysed using a BD FACS Aria (GJIC, BD
Biosciences). A 405nm laser was used for LY excitation and
emission was measured using a 515–545nm band pass filter. Gap
junction intercellular communication between co-cultured donor
and recipient cells was quantified as the percentage of LY and
PKH67 double-labelled cells.
Statistical analysis
All data presented are from single or paired experiments
performed in triplicate, or from 2–3 separate experiments in
duplicate. Comparisons between groups were performed using
paired or un-paired two-tailed Student’s t-test. Statistical
significance was taken to represent a P-value o0.05.
RESULTS
Constitutive expression of GEF16 transforms NIH3T3 cells
As discussed earlier NIH3T3 cells can be transformed by either
ectopic expression of constitutively activated RhoA (Sahai et al,
1999) or various other guanidine exchange factors (Brecht et al,
2005). Our results are consistent with these data because they
clearly show that constitutive expression of GEF16 mRNA induces
the formation of multiple transformed foci in NIH3T3 cells after 12
days of growth in the presence of G418 (Figure 1A). Multilayered
transformed G418-resistant colonies were picked for further
analysis and no transformed foci were observed in G418 selected
vector transfected control cells. Comparison of the growth of
vector and GEF16 transfected cells shows that there is no
significant difference in proliferation rates between these two cell
types (Figure 1B; P40.05).
Y27632 inhibits the formation of GEF16 transformed
colonies
Consistent with the work of Sahai et al (1999) our results show that
treatment with 10mM of the ROCK inhibitor, Y27632, for 10 days
suppresses the formation of GEF16 transformed NIH3T3 cell
colonies (Figure 1C). However, it can also be seen that Y27632
inhibits the growth of confluent GEF16 transformed cells, yet these
cells continue to proliferate in identical untreated cultures
(Figure 1D).
Structural analogues of Y27632 inhibit the growth of
GEF16 transformed colonies
Y27632 is a structural analogue of ATP and 64 different analogues
of this inhibitor were synthesised with the intention of evaluating
their ability to inhibit the formation of GEF16 transformed
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Figure 1 The ROCK inhibitor Y27632 suppresses the formation of GEF16 transformed NIH3T3 colonies. (A) NIH3T3 fibroblasts were transformed by
stable transfection with GEF16 cDNA followed by 12 days of growth in the presence of G418. Transformed foci were visualised by Toluidine blue staining
and GEF16 mRNA expression was verified by RT–PCR. (B) Cell AQ
96 growth comparison of vector and GEF16 polyclonal transfected cells (C) Polyclonal
GEF16 transfected NIH3T3 cells were incubated with either 10mM of Y27632 or DMSO control for 10 days and stained with Toluidine blue. (D) GEF16 and
vector transfected cells were seeded in a 96-well plate at 1 10
3 cells per well. These were incubated for 3 days followed by addition of Cell AQ
96 reagent
to determine the starting point for the assay. A measure of 10mM of either Y27632 or DMSO was then added to wells containing both cell types and Cell
AQ
96 absorbance measured at 6, 8 and 10 days. At day 6 cells were confluent, which was determined by phase contrast visual inspection of the cultures at
 20 magnification.
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sNIH3T3 foci. At 10mM, none of the 64 compounds showed any
appreciable growth inhibitory activity (data not shown), yet four
had the ability to suppress the formation of GEF16 transformed
colonies growing in post-confluent cultures (Figure 2A). The
structures of these are shown with YA1 being the most potent and
YA2 the least. Using this simple assay, the ability of YA1 to block
transformed GEF16 colony formation is comparable to that of
Y27632.
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Figure 2 Structural analogues of Y27632 also inhibited the formation of GEF16 transformed colonies but some had reduced ROCK inhibitory activity.
(A) Aliquots of 2.0 10
5 polyclonal GEF16 transfected cells were seeded into 30mm dishes, incubated overnight then treated with 10mM of 64 different
structural analogues of Y27632. Transformed colony formation was assayed by Toluidine blue staining after 10 days. The ROCK inhibitory activity of four of
these compounds (YAs 1–4) with biological activity was compared with Y27632 (B) The kinase inhibitory activity of YA1 was initially evaluated against a
representative selection of 40 human kinases (SelectScreen). (C) Single-point analysis of the kinase inhibitory activity of YAs 1–4 against HGK, p38, ROCKs
1 and 2 and Aurora A.
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In vitro assays of inhibitory activity against ROCK indicated that
YA1, YA3 and YA4 had significantly less activity against this
kinase than Y27632 (Figure 2A). However, paradoxically YA2,
which was least effective at preventing GEF16 colony formation,
had comparable ROCK inhibitory activity to Y27632. On the basis
of these results it was concluded that the ability of compounds
YA1, YA3 and YA4 to inhibit GEF16 colony formation may be
either because of inhibitory effects against unidentified kinases or
other alternative cellular targets.
YA1, YA3 and YA4 have inhibitory activity against p38,
HGK and Aurora A kinases whereas YA2 targets HGK and
ROCKs 1 and 2
As YA1, YA3 and YA4 are structurally very similar and YA1 was
the most potent at blocking GEF16 transformed colonies
(Figure 2A), an in vitro kinase inhibitory assay was performed
on this compound against a representative selection of 40 human
kinases (SelectScreen) (Figure 2B). These data show that at 10mM,
YA1 had maximal inhibitory activity against p38 a (MAPK14)
(72%), HGK (MAP4K4) (63%) and Aurora A (44%) and also
confirmed the reduced ROCK inhibitory activity of YA1 shown in
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Figure 3 YA1 irreversibly suppresses the formation of GEF16 transformed NIH3T3 colonies. (A) Polyclonal GEF16 transfected cells were plated at
2.0 10
5 cells per 30mm dish and 10mM of YA1 added for 2, 4, 6, 8 and 10 days, respectively. After this incubation period the compound was then
removed from the culture media and cells maintained in normal growth media for a further 10 days. (B) Cell AQ
96 proliferation assay of sub-confluent
cultures treated with DMSO or inhibitor for the same time interval. (C) Flow cytometric analysis of either YA1 or Y27632 (10mM)-treated GEF16 cells.
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sFigure 2A (B40%). An additional single-point analysis of the
inhibitory activity of 10mM of compounds YA’s 1, 2, 3 and 4 against
p38, HGK, Aurora A, and ROCKs 1 and 2 confirmed that YA2 had
the greatest activity against ROCK’s 1 and 2. YAs1, 3 and 4 all have
significant activity against p38, HGK and Aurora A, but show less
activity against ROCKs than YA2. Interestingly, YA2 also has the
greatest inhibitory activity against HGK (Figure 2C) but is the least
effective at preventing colony formation (Figure 2A). Paradoxi-
cally, even though YA1 is the most potent in cell-based assays, it
has roughly equivalent activity to YA4 against HGK and p38 yet
has less inhibitory activity against Aurora A than YA4. These
observations suggest that, although the three kinases identified as
targets of YA1 cannot be excluded as having a role in the formation
of GEF16 transformed colonies, it is clear that this compound may
also affect other, as yet, unidentified cellular targets.
Transient exposure of GEF16 cells to either YA1 or Y27632
eliminates transformed colony forming cells from
polyclonal GEF16 cells
Freshly plated GEF16 polyclonal cells were treated with 10mM of
YA1 for 2, 4, 6, 8 and 10 days, respectively, after which the
compound was removed from the culture media and the cells
maintained in normal media for a further 10-day chase period.
This shows a progressive decrease in the number of transformed
foci associated with increased time of exposure to the compound
(Figure 3A) and indicates that YA1 not only inhibits the formation
of transformed foci but, on withdrawal, also prevents transformed
foci from reforming. Significantly, there is no detectable difference
in growth rates of sub-confluent GEF16 polyclonal cells treated
with either inhibitor YA1 or DMSO control (Figure 3B) (P40.05),
and flow cytometry shows no evidence of alterations in cell cycle or
the accumulation of an apoptotic sub-G1 population (Figure 3C).
In Figure 3A the number of cells per dish increases with each
successive inhibitor-treatment time interval before withdrawal of
the compound. To remove this variable and to ensure that each
10-day chase period starts with the same number of inhibitor-
treated cells, GEF16 polyclonal cells were treated with either
inhibitor YA1 or Y27632 for 2, 4, 6, 8 and 10 days. After this, cells
were detached, re-seeded at 2 10
5 per well in 6-well plates and
then maintained in the absence of inhibitors for a 10-day chase
period. This shows suppression of transformed focus formation by
either YA1 or Y27632 treatment, which correlates with the
duration of exposure (Figure 4A). Collectively these observations
are the first to show that transient treatment with Y27632 or YA1
permanently suppresses transformed colony formation and does
not involve cell killing.
YA1 eliminates pre-formed transformed colonies from
GEF16 polyclonal cells
The results have so far shown that both Y27632 and YA1 can
prevent transformed colonies from forming and that this effect
persists. To evaluate the effects of these compounds on pre-formed
colonies, polyclonal GEF16 NIH3T3 transformed colonies were
allowed to form for 10 days and then exposed to Y27632 or YA1 for
3 and 6 days. It can be seen that Y27632 has very little effect on
pre-formed transformed colonies whereas YA1 causes a marked
reduction in their numbers (Figure 4B). Vector transfected
polyclonal NIH3T3 cells are included as a control and show no
difference between inhibitor treated and DMSO controls.
YA1 has minimal effects on cells derived from single
GEF16 transformed colonies
Single transformed colonies were picked from GEF16 polyclonal
NIH3T3 cells and expanded (Figure 5A). These were plated and
inhibitor YA1 added either immediately or after 10 days when the
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Figure 4 YA1 and Y27632 irreversibly suppress the formation of GEF16 transformed NIH3T3 colonies whereas, unlike Y27632, YA1 eliminates pre-
existing transformed colonies. (A) Polyclonal GEF16 transfected cells were seeded at 2.0 10
5 cells per 30mm dish and incubated overnight. A measure of
10mM YA1 or Y27632 was then added to each of these for 2, 4, 6, 8 and 10 days, respectively, where upon the cells were detached with trypsin and re-
plated at a density of 2.0 10
5 cells. After a further 10 days culture in the absence of inhibitors the cells were stained with Toluidine blue. (B) Polyclonal
GEF16 and vector transfected cells were seeded at 2.0 10
5 cells per 30mm dish and incubated for 10 days after which 10 or 20mM of either, YA1, Y27632
or DMSO control was added. These were incubated for 3 or 6 days then stained with Toluidine blue.
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Figure 5 The growth suppressive effects of YA1 on single transformed colony-derived GEF16 NIH3T3 cells and polyclonal Ras transformed NIH3T3 cells
are more pronounced when these are co-cultured with non-transformed cells. (A) Single transformed colonies were picked from 10-day cultures of GEF16
polyclonal NIH3T3 cells and expanded. These cells were then seeded at 2.0 10
5 cells per 30mm dish and treated with 10mM of YA1 or DMSO control
either immediately or after 10 days in culture. Duplicate wells were collected for flow cytometry. (B) A total of 2 10
5 cells per well were plated consisting
of increasing numbers of non-transformed vector cells co-cultured with decreasing numbers of single transformed colony-derived GEF16 cells. These were
treated with 10mM of either YA1 or DMSO for 10 days. (C) The same co-culture experiment described in (B) was performed substituting polyclonal Ras
transformed NIH3T3 cells for GEF16 transformed cells.
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scells were post-confluent. It can be seen that this has a modest
effect when added to low density cultures whereby these do not
achieve the same saturation density as control cells. However,
addition of YA1 to post-confluent cultures has no discernible effect
when compared with controls. Flow cytometry shows YA1 has no
effect on the cell cycle and no apoptotic sub-G1 population is seen
in cultures treated either pre- or post-confluence.
YA1 suppresses the growth of monoclonal GEF16 and
polyclonal Ras transformed cells when these are
co-cultured with non-transformed NIH3T3 cells
Non-transformed vector cells mixed with decreasing numbers of
cells expanded from single GEF16 transformed colonies were
treated with inhibitor YA1 or DMSO and incubated for 10 days. It
can be seen that YA1 causes a marked reduction in the final
saturation density of the cultures and that this is dependent on the
number of transformed cells plated (Figure 5B). Comparing these
results to those shown in Figure 5A indicates that YA1 is more
effective at suppressing the growth of transformed cells when these
are in contact with non-transformed cells. Figure 5C shows that
YA1 produces the same growth suppressive effects on Ras
transformed NIH3T3 cell colonies as with GEF16 transformed
cells and that these are also dependent on contact with non-
transformed cells. The phase contrast images also show how
YA1-treated Ras transformed cells regain both contact inhibition
and polarity.
YA1 increases intercellular GJIC between transformed and
non-transformed cells
Figure 6A shows the effect of either YA1 or DMSO control on the
extent of dye transfer from co-cultured donor LY-labelled GEF16
single colony transformed cells to recipient PKH67 stained non-
transformed cells. It can be seen from Figure 6B that YA1-treated
cultures have approximately three times the number of double
LY/PKH67-labelled cells when compared with DMSO control
(Po0.05). This indicates an increase in the transfer of dye from
LY to PKH67 stained cells, which is consistent with an inhibitor-
induced increase in GJIC.
DISCUSSION
Our data are the first to show that transient treatment with either
the ROCK inhibitor, Y27632, or specific structural analogues of
this compound not only prevents the formation of transformed
NIH3T3 colonies, but also colonies do not form when the
compounds are withdrawn. Most surprising was that, unlike
Y27632, the effects of YA1, 3 and 4, occur independent of ROCK
inhibitory activity and do not involve cell killing. Furthermore,
YA1 has the additional property of eliminating pre-existing
transformed colonies and this effect is also not produced by cell
killing.
In an attempt to improve the potency of Y27632, 64 different
structural analogues were synthesised of which 3 were initially
shown to have similar effects to Y27632 on transformed colony
formation, yet these compounds had lower ROCK inhibitory
activity. Paradoxically, although YA2 had equivalent ROCK
inhibitory activity to Y27632, it was much less effective at
preventing transformed colony formation. Clearly this could be
due to the pharmacodynamic propertes of this compound
although an alternative explanation could be that the effects of
Y27632 are not entirely because of ROCK inhibition. For example,
in addition to ROCK’s 1 and 2 it is known that at 10mM Y27632 also
has significant inhibitory activity against 16 other kinases
including the protein kinase C (PKC) isoforms b, e and Z, and
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Figure 5 Continued.
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sthe myotonic dystrophy kinase-related Cdc42-binding kinases
Cdc42 BPA (MRCKA) and Cdc42 BPB (MRCKB). (For a complete
list of these see supplementary information URL: http://www.
invitrogen.com/etc/medialib/en/filelibrary/pdf.Par.96408.File.dat/
SelectScreen_Data_193.pdf). The Cdc42-activated MRCK kinases
are particularly relevant because, similar to ROCKs, they promote
myosin-dependent cell motility and indicate a point of conver-
gence between RhoA and Cdc42 signalling (Wilkinson et al, 2005).
Thus, the observed inability of compound YA2 to prevent the
formation of transformed colonies could be due to its lack of
inhibitory activity against one or more of these alternative target
kinases. Indeed, PKC epsilon undergoes 94% inhibition by 10mM
Y27632 and it has been shown that increased activity of this kinase
is causally associated with calpain inhibitor-induced transforma-
tion of NIH3T3 cells (Hiwasa et al, 2002). In addition, GEF16
possesses a potential Cdc42-binding motif (Blanke and Jackle,
2006) and we have shown that GEF16 specifically activates Cdc42
in vitro and in cells (See Supplementary Data Figure 1; manuscript
in preparation). Interestingly, activated Cdc42 is also known to
promote the activation of p38 (Hall, 2005), which is entirely
consistent with the p38 inhibitory activity of compounds YA1, YA3
and YA4.
However, it is clear from Figure 2 that there is not an obvious
relationship linking any of the kinases identified as being the sole
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Figure 6 YA1 stimulates GJIC between transformed and non-transformed cells. (A) Cells derived from a single GEF16 transformed colony were
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starget responsible for the biological activity of YA1. This is either
the result of inhibition of an, as yet, unidentified kinase or may
reflect a particular combination of inhibitory activities.
The observed minimal toxicity combined with persistence of the
suppressive effects of the YA compounds on transformed colony
formation, prompted an investigation into the rationale behind
this effect. As discussed earlier, the ability of non-transformed cells
to establish GJIC with transformed cells has been shown to
suppress the transformed properties of cells without cell killing
(Sakamoto et al, 1999). Thus, we hypothesised that inhibitor
induced increased GJIC between transformed and non-trans-
formed NIH3T3 cells is the most plausible mode of action
(Sakamoto et al, 1999). To address this question we developed
the LY/PKH67 vital dye staining method. Lucifer yellow cannot
penetrate cell membranes (Raptis et al, 1994) and PKH67 remains
very stably associated with labelled cells (Rousselle et al, 2001).
Our method clearly shows that YA1 induces increased accumula-
tion of double LY/PKH67-labelled cells when compared with
DMSO-treated controls, which strongly supports a YA1-mediated
increase in GJIC between transformed and non-transformed cells.
If this rationale is correct, treatment of single colony-derived
GEF16 transformed NIH3T3 cells with either YA1 or Y27632
should have little or no effect when these are grown in the absence
of non-transformed cells and results shown in Figure 5A support
this. However, the growth inhibitory effects of YA1 on single
colony-derived transformed cells are clearly restored when these
are co-cultured with non-transformed NIH3T3 cells (Figure 5B).
A surprising and unexpected result was the ability of this
compound to eliminate pre-formed transformed colonies from
GEF16 polyclonal cells (Figure 5). Neither Y27632 nor any of the
other compounds tested (data not shown) had this property, which
clearly distinguishes YA1 from all the others and suggests an
additional mode of action.
Is there any evidence that the various kinase targets described
may participate in transformation-induced disruption of gap
junctions? Inhibition of ROCK activation by Y27632 has been
shown to facilitate the formation of gap junctions in corneal
epithelium (Anderson et al, 2002). Furthermore, H-Ras-induced
disruption of gap junctions in rat liver epithelial cells can be
reversed by treatment with the p38 inhibitor SB203580 (Lee et al,
2004). We found that SB203580 had some activity against GEF16
transformed colonies although this was much less than YA1 (see
Supplementary Data Figure 2). Considering that 10mM SB203580
has 420-fold more p38 inhibitory activity than YA1 at the same
concentration (Tocris Biosciences, Bristol, UK; Data Sheet) this
implies that p38 inhibition alone does not explain the inhibitory
activity of YA1 against transformed colonies.
It is very significant that YA1 was also highly effective at
preventing the formation of Ras transformed NIH3T3 colonies,
which indicates that the activity of these compounds is not
restricted to a specific GEF but instead targets Rho/Ras-mediated
transformation in general.
In summary, our data support the hypothesis that specific
inhibitors with the ability to modulate the activity of selected
kinases may form the basis of a novel strategy for cancer chemo-
prevention. The effect is most likely produced by enhancement of
the ability of non-transformed cells to establish GJIC with
transformed cells and it can clearly persist after withdrawal of
the inhibitor. Most importantly, if these findings can be translated
into an in vivo cancer chemoprevention strategy, it suggests that
the active agent may not need to be administered continuously.
Furthermore, we would also suggest that inhibitors of this type
should be explored as a means of suppressing both the formation
and growth of metastases. It is highly significant that Y27632 has
been shown to suppress the development of metastases in vivo
(Itoh et al, 1999; Ogawa et al, 2007) with the rationale being that
ROCK inhibition suppresses the migration of tumour cells. Our
data indicate that if Y27632 or our novel compounds can promote
intercellular communication between metastatic cells and normal
cells at distant sites of invasion, this could provide an additional
unexplored level of growth control during the metastatic process
and we are currently exploring this hypothesis.
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